Advances in End-Stage Renal Diseases 2001: International by C. Ronco, N.W. Levin

By C. Ronco, N.W. Levin

Reprint of: Blood Purification 2001, Vol. 19, No. 2 during this well timed ebook, quite a few subject matters regarding ESRD are mentioned, together with vascular illness and atherosclerosis in uremia, results of hemodialysis sufferers in several international locations, malnutrition in addition to oxidative rigidity and persistent irritation as probability elements for heart problems. furthermore, the potential for utilizing peritoneal dialysis as a primary remedy modality for ESRD is debated, including the advantages that may be completed with day-by-day dialysis. additional themes contain the main complicated ideas for electrolyte tracking and profiling in hemodialysis in addition to the therapy of acute renal failure, describing the recent acute dialysis caliber initiative. one other vital a part of this book is an argument on no matter if hemoglobin degrees in pre-ESRD and hemodialysis sufferers may be normalized or no longer, by way of a dialogue of the aptitude long term merits of a brand new expertise coupling hemoperfusion with hemodialysis, using a brand new sorbent machine. A definition of the genuine application of those applied sciences in day-by-day medical perform and whether or not they are economically cheaper with current repayment rules rounds off the displays. Being the second one quantity during this sequence (see additionally the volumes for the years 2000, 2002 and 2003), this booklet is meant to function a syllabus for meetings in addition to a tutorial software for fellows and citizens. while, it offers a such a lot worthy replace on fresh perform and expertise for all physicians interested in the sphere of hemodialysis.

Show description

Read or Download Advances in End-Stage Renal Diseases 2001: International Conference on Dialysis Iii, Miami Beach, Fla., January 2001 PDF

Best endocrinology & metabolism books

TRAIL (TNF-Related Apoptosis-Inducing Ligand)

The invention of path (TNF similar Apoptosis Inducing Ligand), often known as Apo-2, is in an period of severe examine simply because path induces many melanoma cells to endure programmed cellphone dying (apoptosis), whereas having no influence on common cells. this significant protein merits wide overview at a formative time within the devlopement of our wisdom pertaining to its mechanism of motion and the ways that it may be used as a melanoma chemotherapeutic agent.

Pharmacotherapy of Obesity: Options and Alternatives

Drug remedy of weight problems continues to be a debatable subject. evaluations diversity from advocating life-long therapy of weight problems with a unmarried drug or drug blend, to opposing drug remedy of weight problems as a result of its inevitable use as "lifestyle medications. " Clarifying the talk, Pharmacotherapy of weight problems: concepts and choices explores present and destiny thoughts for drug therapy for weight problems within the context of pathophysiology and scientific specifications after which places them into viewpoint opposed to to be had replacement remedies.

Emotions, Hormones and Atherosclerosis

The rise of emotional pressure has nerve-racking results at the neurohumoral rules of metabolic approaches, specially when it comes to the cardiovascular approach, and raises the alterations of organisms constructing atherosclerosis. This publication reports the consequences at the cardiovascular process (in IHD sufferers) attributable to feelings of numerous organic traits (both confident and negative).

Extra info for Advances in End-Stage Renal Diseases 2001: International Conference on Dialysis Iii, Miami Beach, Fla., January 2001

Example text

Although not specifically related to epoetin therapy, the data do suggest that dialysis patients with more profound anemia have an increased mortality rate, longer duration of hospital admission, and lower quality-of-life scores. If one examines Macdougall Fig. 4. Mean monthly epoetin doses in the US Normal Hematocrit Trial of 1,233 hemodialysis patients. There was a significant difference in the mean doses between the two groups from 1 month onwards (p ! 001). Error bars indicate 95% confidence intervals of the mean.

J Am Soc Nephrol 1999;10:2392–2395. 8 Jacobs C: Normalization of haemoglobin: Why not? Nephrol Dial Transplant 1999;14(suppl 2):75–79. 9 Ritz E, Schwenger V: The optimal target hemoglobin. Sem Nephrol 2000;20:382–386. 10 Macdougall IC, Ritz E: The Normal Hematocrit Trial in dialysis with cardiac disease. Are we any the less confused about the target haemoglobin. Nephrol Dial Transplant 1998;13: 3030–3033. 11 Nissenson AR, Besarab A, Bolton WK, Goodkin DA, Schwab SJ: Target hemoglobin/hematocrit during EPO therapy.

13 Macdougall IC, Ritz E: The Normal Haematocrit Trial in dialysis patients with cardiac disease: Are we any the less confused about target haemoglobin? Nephrol Dial Transplant 1998; 13:3030–3033. 14 Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300:573–578. 15 Eschbach JW, Glenny R, Robertson T, Guthrie M, Rader B, Evans R, Chandler W, Davidson R, Easterling T, Denney J, Schneider G: Normalizing the hematocrit in hemodialysis patients with EPO improves quality of life and is safe.

Download PDF sample

Advances in End-Stage Renal Diseases 2001: International by C. Ronco, N.W. Levin
Rated 4.84 of 5 – based on 25 votes